• Earlier this month, “Men’s Fitness,” reviewed the unbuzzd clinical trial and described the early study findings as “promising.”
  • Results showed that estimated blood alcohol concentration was significantly lower and participants experienced improved self-rated alertness and lower headache severity.
  • For operators in this space, the stakes reach beyond the morning after.

LOS ANGELES, CA - November 3, 2026 (NEWMEDIAWIRE) - Most recovery drinks promise relief after a night out, yet few have been tested against a placebo in a registered human trial. One that has is now getting a close look from a major fitness publication. Quantum BioPharma (NASDAQ: QNTM), a biopharmaceutical company developing therapies for neurodegenerative, metabolic and alcohol misuse disorders, has invented unbuzzd, a supplement drink designed to support alcohol metabolism, and keeps royalty and equity interests in the consumer brand.

Earlier this month, “Men’s Fitness,” reviewed the unbuzzd clinical trial and described the early study findings as “promising.” The magazine notes that “a small clinical trial found improvements in alcohol readings, alertness, and headache symptoms . . . [offering] early encouragement. Researchers reported lower estimated blood alcohol concentrations at several time…

Read More

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer

The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM

Forward Looking Statements

Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading "Risk Factors" discussed under the caption "Item 1A. Risk Factors" in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption "Item 1A. Risk Factors" in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law.

View the original release on www.newmediawire.com